BR9909789A - Método de purificação eficiente de adenovìrus - Google Patents

Método de purificação eficiente de adenovìrus

Info

Publication number
BR9909789A
BR9909789A BR9909789-3A BR9909789A BR9909789A BR 9909789 A BR9909789 A BR 9909789A BR 9909789 A BR9909789 A BR 9909789A BR 9909789 A BR9909789 A BR 9909789A
Authority
BR
Brazil
Prior art keywords
adenovirus
solution
chromatography resin
purification method
sample solution
Prior art date
Application number
BR9909789-3A
Other languages
English (en)
Inventor
Miguel E Carrion
Imre Kovesdi
Marilyn Menger
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of BR9909789A publication Critical patent/BR9909789A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B01D15/345—Perfusive chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N2030/621—Detectors specially adapted therefor signal-to-noise ratio
    • G01N2030/625—Detectors specially adapted therefor signal-to-noise ratio by measuring reference material, e.g. carrier without sample
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Dry Shavers And Clippers (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<B> MéTODO DE PURIFICAçãO EFICIENTE DE ADENOVìRUS <D> Um método de enriquecimento de uma solução de um adenovírus compreendendo a plicação de uma solução misturada compreendendo adenovírus e pelo menos um tipo indesejável de biomolécula a uma resina de cromatografia de troca aniónica contendo uma porção de ligação selecionada do grupo que consiste em dimetilaminopropil, dimetilaminobutil, dimetilaminoisobutil, e dimetilamino pentil e eluição do adenovírus a partir da resina de cromatografia. Também é fornecido um método de purificação de adenovírus de células infectadas por adenovírus compreendendo a lise de tais células, aplicação do produto de lise de célula a uma resina de cromatografia única, eluindo o adenovírus da resina de cromatografia, e coletando uma fração contendo adenovírus que é substancialmente tão pura quanto o adenovírus purificado por gradiente de densidade de CsCl triplo. O presente método também apresenta um método de quantificar de forma precisa o número de partículas adenovirais em uma solução de adenovírus compreendendo a aplicação e eluição de uma resina de cromatografia de troca aniónica uma solução de amostra de adenovírus, comparando a bsorvência da solução de amostra de adenovírus e a absorbância de uma solução padrão de adenovírus, e quantificação do número de partículas adenovirais na solução de amostra.
BR9909789-3A 1998-04-22 1999-04-22 Método de purificação eficiente de adenovìrus BR9909789A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8262898P 1998-04-22 1998-04-22
PCT/US1999/008843 WO1999054441A1 (en) 1998-04-22 1999-04-22 Efficient purification of adenovirus

Publications (1)

Publication Number Publication Date
BR9909789A true BR9909789A (pt) 2000-12-26

Family

ID=22172352

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909789-3A BR9909789A (pt) 1998-04-22 1999-04-22 Método de purificação eficiente de adenovìrus

Country Status (20)

Country Link
US (3) US6383795B1 (pt)
EP (1) EP1073721B1 (pt)
JP (1) JP2002512361A (pt)
AT (1) ATE303434T1 (pt)
AU (1) AU756889B2 (pt)
BG (1) BG104928A (pt)
BR (1) BR9909789A (pt)
CA (1) CA2328462C (pt)
DE (1) DE69927013T2 (pt)
EA (1) EA200001096A1 (pt)
EE (1) EE200000605A (pt)
HU (1) HUP0102209A2 (pt)
IL (1) IL139040A0 (pt)
IS (1) IS5673A (pt)
MX (1) MXPA00010338A (pt)
NO (1) NO20005295L (pt)
PL (1) PL343630A1 (pt)
SK (1) SK15682000A3 (pt)
WO (1) WO1999054441A1 (pt)
ZA (1) ZA200005363B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737107T2 (de) * 1996-11-20 2007-07-12 Introgen Therapeutics Inc., Austin Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP3547715B2 (ja) * 2001-03-06 2004-07-28 榮 新垣 ベクター精製用装置及び方法
JP2004538005A (ja) * 2001-08-08 2004-12-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア シアル酸に結合するタンパク質を有するウイルスベクターの精製法
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
EP2241330A1 (en) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
AU2004249199B2 (en) * 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
EP1649028B1 (en) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviral vector-based vaccines
WO2005029573A1 (en) * 2003-09-19 2005-03-31 Tinggi Technologies Private Limited Fabrication of semiconductor devices
EP1687032B1 (en) 2003-11-14 2010-02-24 Genvec, Inc. Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
ES2329607T3 (es) * 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
CA2563396A1 (en) 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
GB0411081D0 (en) * 2004-05-18 2004-06-23 Glaxo Group Ltd Novel apparatus
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
JP4626350B2 (ja) * 2005-03-22 2011-02-09 ソニー株式会社 ハイブリダイゼーション検出に適する反応部などを有する流路系、該流路系を用いるハイブリダイゼーション検出装置
CN101218256B (zh) 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
EP1912675B1 (en) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC B-cell reduction using cd37-specific and cd20-specific binding molecules
BRPI0618441B8 (pt) 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
EP1808697A1 (en) * 2006-01-13 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Use of an ion exchange matrix for determining the concentration of virus particles and/or virus antigens
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US20090148447A1 (en) * 2007-07-06 2009-06-11 Trubion Pharmaceuticals, Inc. Binding Peptides Having a C-terminally Disposed Specific Binding Domain
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
JP6013733B2 (ja) * 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
PL2350268T3 (pl) * 2008-11-03 2015-05-29 Crucell Holland Bv Sposób wytwarzania wektorów adenowirusowych
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
NZ601424A (en) 2010-02-15 2014-07-25 Crucell Holland Bv Method for the production of ad26 adenoviral vectors
TW201823463A (zh) 2010-03-23 2018-07-01 美商英翠克頌公司 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途
EP3450568A3 (en) 2011-03-04 2019-04-24 Intrexon Corporation Vectors conditionally expressing protein
CN102590431B (zh) * 2012-02-10 2014-04-02 济南康众医药科技开发有限公司 一种治疗咳嗽的中药药物组合物检测方法
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
KR20240015743A (ko) 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
GB201806736D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method for virus purification
JP2022521268A (ja) 2019-02-21 2022-04-06 アンリーシュ イミュノ オンカリティクス，インコーポレイテッド 腫瘍溶解性アデノウイルスベクター及び使用法
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
JP2022534741A (ja) 2019-05-28 2022-08-03 セレクタ バイオサイエンシーズ インコーポレーテッド 減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物
WO2021011436A1 (en) * 2019-07-12 2021-01-21 Sangamo Therapeutics, Inc. Separation and quantification of empty and full viral capsid particles
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788223A (en) * 1985-07-26 1988-11-29 Rohm And Haas Company Low-rinse, high-capacity, weakly basic acrylic ion exchange resin
US5225989A (en) * 1988-05-19 1993-07-06 Fanuc Ltd. Apparatus and method for performing simultaneous control of control axes of a machine tool
US5019270A (en) 1989-07-06 1991-05-28 Perseptive Biosystems, Inc. Perfusive chromatography
US5228989A (en) 1989-07-06 1993-07-20 Perseptive Biosystems, Inc. Perfusive chromatography
AU654323B2 (en) * 1991-01-04 1994-11-03 Perseptive Biosystems, Inc. Sulfonamide bonded hydrophilic coating
US5445732A (en) 1992-06-19 1995-08-29 Sepracor Inc. Passivated porous polymer supports and methods for the preparation and use of same
US5268097A (en) 1992-06-19 1993-12-07 Sepracor Inc. Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US6143548A (en) * 1995-08-30 2000-11-07 Genzyme Corporation Chromatographic purification of adeno-associated virus (AAV)
CA2184132C (en) * 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
AU3447097A (en) 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
DE69737107T2 (de) * 1996-11-20 2007-07-12 Introgen Therapeutics Inc., Austin Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
JP2003523169A (ja) 1998-12-31 2003-08-05 アバンテイス・フアルマ・エス・アー ウイルス粒子の分離法
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee

Also Published As

Publication number Publication date
ZA200005363B (en) 2001-09-25
PL343630A1 (en) 2001-08-27
US6586226B2 (en) 2003-07-01
BG104928A (en) 2001-09-28
NO20005295D0 (no) 2000-10-20
US7141406B2 (en) 2006-11-28
IS5673A (is) 2000-10-20
DE69927013T2 (de) 2006-06-29
HUP0102209A2 (hu) 2001-09-28
US20030203469A1 (en) 2003-10-30
EA200001096A1 (ru) 2001-04-23
US20020034735A1 (en) 2002-03-21
CA2328462C (en) 2010-11-09
EE200000605A (et) 2002-04-15
ATE303434T1 (de) 2005-09-15
US6383795B1 (en) 2002-05-07
WO1999054441A8 (en) 2000-02-24
SK15682000A3 (sk) 2001-05-10
IL139040A0 (en) 2001-11-25
AU3662099A (en) 1999-11-08
NO20005295L (no) 2000-11-30
DE69927013D1 (de) 2005-10-06
MXPA00010338A (es) 2005-06-17
CA2328462A1 (en) 1999-10-28
AU756889B2 (en) 2003-01-23
WO1999054441A1 (en) 1999-10-28
JP2002512361A (ja) 2002-04-23
EP1073721A1 (en) 2001-02-07
EP1073721B1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
BR9909789A (pt) Método de purificação eficiente de adenovìrus
Toyo'oka et al. High-performance liquid chromatography and fluorometric detection of biologically important thiols, derivatized with ammonium 7-fluorobenzo-2-oxa-1, 3-diazole-4-sulphonate (SBD-F)
Nordberg et al. On the distribution of cadmium in blood
Hynes et al. Density and cell cycle dependence of cell surface proteins in hamster fibroblasts
Lawrence et al. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells
Bonas et al. Separation and estimation of certain guanidino compounds. Application to human urine
AU5585599A (en) Stable isotope metabolic labeling for analysis of biopolymers
CA2246961A1 (en) Sample processing method using ion exchange resin
Langenbach et al. Gangliosides and their cell density-dependent changes in control and chemically transformed C3H/10T1/2 cells
Taketa et al. Acetylated hemoglobins in feline blood
Ceccarini Appearance of smaller mannosyl-glycopeptides on the surface of a human cell transformed by simian virus 40.
Mroczkowska et al. Blood–brain barrier controls carnitine level in the brain: a study on a model system with RBE4 cells
Yang et al. The biochemical and genetic basis for the microheterogeneity of human R-type vitamin B12 binding proteins
Katz et al. Comparative serum and urine analyses by dual-detector anion-exchange chromatography
Matysik et al. Stepwise gradient development in thin-layer chromatography: II. Two-dimensional gradients for complex mixtures
Okamoto et al. Evaluation of phenyldimethylethoxysilane treated high-performance thin-layer chromatographic plates. Application to analysis of flavonoids in Scutellariae radix
Murakami et al. An isozyme of hexokinase specific for the human red blood cell (HKR)
Stanley Carbohydrate heterogeneity of vesicular stomatitis virus G glycoprotein allows localization of the defect in a glycosylation mutant of CHO cells
Rickwood et al. The modification of nuclear proteins by ADP‐ribosylation
Murata et al. Liquid chromatographic assay for constituent disaccharides of hyaluronic acid and chondroitin sulphate isomers
Hazelett et al. Improved separation of acetaldehyde‐induced hemoglobin
Petrovic et al. A new general method for separation of nucleic acids
Azen et al. Genetic polymorphism of vitamin B 12 binding (R) proteins of human saliva detected by isoelectric focusing
Berg et al. The structure and properties of 27S and larger iodoproteins in the thyroid gland
Sandvoss et al. Small‐scale two‐dimensional liquid chromatography for a preparative re‐purification of a highly labile tritium‐labeled compound

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]